![It's not time to abandon routine screening mammography in average-risk women in their 40s | MDedge ObGyn It's not time to abandon routine screening mammography in average-risk women in their 40s | MDedge ObGyn](https://cdn.mdedge.com/files/s3fs-public/obgm03210-pearlman_web_t1.jpg)
It's not time to abandon routine screening mammography in average-risk women in their 40s | MDedge ObGyn
![Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial | npj Breast Cancer Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial | npj Breast Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41523-021-00288-8/MediaObjects/41523_2021_288_Fig1_HTML.png)
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial | npj Breast Cancer
External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | PLOS ONE
![Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial | Journal of Clinical Oncology Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2019/jco.2019.37.issue-26/jco.19.00647/20190827/images/large/jco.19.00647t4.jpeg)
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial | Journal of Clinical Oncology
External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | PLOS ONE
![Cancers | Free Full-Text | Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy Cancers | Free Full-Text | Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy](https://pub.mdpi-res.com/cancers/cancers-14-03848/article_deploy/html/images/cancers-14-03848-g001.png?1660053841)
Cancers | Free Full-Text | Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy
![Cancers | Free Full-Text | Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review Cancers | Free Full-Text | Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review](https://www.mdpi.com/cancers/cancers-14-01898/article_deploy/html/images/cancers-14-01898-g001.png)
Cancers | Free Full-Text | Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
![Surgical Predictive Model for Breast Cancer Patients Assessing Acute Postoperative Complications: The Breast Cancer Surgery Risk Calculator | SpringerLink Surgical Predictive Model for Breast Cancer Patients Assessing Acute Postoperative Complications: The Breast Cancer Surgery Risk Calculator | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1245%2Fs10434-021-09710-8/MediaObjects/10434_2021_9710_Fig1_HTML.png)
Surgical Predictive Model for Breast Cancer Patients Assessing Acute Postoperative Complications: The Breast Cancer Surgery Risk Calculator | SpringerLink
![Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/1aaed949-5c4f-462b-9551-ec8e88b8e698/tbj.v26.6.cover.jpg?trick=1680548507287)
Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library
![Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study - Modern Pathology Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study - Modern Pathology](https://mp.uscap.org/cms/asset/9ae860b0-dcac-4b6d-9b51-565655ad9366/gr1.jpg)